Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBITDA MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) Return on Sales (2022 - 2025)

Summit Therapeutics (SMMT) has disclosed Return on Sales for 2 consecutive years, with 7291.44% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Sales rose 725846.0% year-over-year to 7291.44%, compared with a TTM value of 7291.44% through Sep 2025, up 725846.0%, and an annual FY2022 reading of 111.75%, down 6277.0% over the prior year.
  • Return on Sales was 7291.44% for Q3 2025 at Summit Therapeutics, down from 14050.56% in the prior quarter.
  • Across five years, Return on Sales topped out at 14050.56% in Q2 2025 and bottomed at 14.58% in Q1 2024.